Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/07/26	$1.940	-2.02%	6,786
01/07/26	$1.980	-4.81%	37,926
30/06/26	$2.080	-5.45%	108,768
29/06/26	$2.200	-8.33%	46,423
26/06/26	$2.400	-4.76%	68,980

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 18:09:08 02/07/2026 +04			5-day change	1st Jan Change
1.940 ^USD	-2.02%		-23.02%	-64.21%

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	12.62M 11.08M 10.2M 9.5M 17.92M 1.2B 18.29M 123M 47.53M 589M 47.39M 46.36M 2.05B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	9.05M 7.95M 7.31M 6.82M 12.85M 860M 13.11M 87.97M 34.08M 422M 33.98M 33.25M 1.47B	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	64.62%	Yield 2024 *	-	Yield 2025	-

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
04-23	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
04-11	Exicure, Inc. Announces Management Changes	CI
03-28	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
03-26	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-25	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-18	Exicure appoints Jung Soo Kim as CEO and president	RE
02-18	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
02-18	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI
02-11	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026	CI

16/08/22	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
29/03/22	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
13/12/21	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
23/11/21	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
17/05/21	EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news : Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

06-30	Exicure Announces Board and Committee Changes	AQ
06-11	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
06-02	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
04-23	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
04-03	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ

02/08/21	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
02/08/21	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
02/08/21	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
02/08/21	Ipsen : accord de collaboration avec Exicure
02/08/21	Dernière ligne droite avant la coupure aoûtienne

1 day	-2.02%
1 week	-23.02%
Current month	-6.73%
1 month	-37.62%
3 months	-53.70%
6 months	-65.23%
Current year	-64.21%

1 week	1.77	2.88
1 month	1.71	3.2
Current year	1.71	6.64
1 year	1.71	9.5
3 years	1.44	36
5 years	1.44	297
10 years	1.44	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	11/02/2026
Josephine Cardarelli PSD	President	-	06/10/2025
Gyuyeob Lee DFI	Director of Finance/CFO	40	11/02/2026

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	21/08/2023
Jungsoo Kim BRD	Director/Board Member	-	11/02/2026
Gyeung Seog Cheon BRD	Director/Board Member	-	09/02/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
02-16	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%
01-21	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%
01-16	EXICURE HITRON, INC.	Sell	Company	734,747	11.6298%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	-2.02%	-23.02%	-67.45%	-68.46%	12.62M
ARGENX SE	+4.13%	+5.60%	+76.49%	+136.29%	56.21B
WUXI APPTEC CO., LTD.	+0.55%	+8.49%	+77.09%	+100.93%	55.38B
BIONTECH SE	+4.21%	+9.12%	-9.28%	-8.91%	23.75B
INSMED INCORPORATED	+2.80%	+5.70%	+12.41%	+432.19%	23.19B
WUXI BIOLOGICS (CAYMAN) INC.	+3.64%	+8.34%	+39.81%	-5.88%	18.14B
GENMAB A/S	+3.62%	+8.28%	+43.79%	-28.13%	16.84B
PHARMAESSENTIA CORPORATION	+1.49%	+17.24%	+174.91%	+344.55%	15.86B
EXELIXIS, INC.	+3.39%	+4.42%	+25.47%	+190.56%	13.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.20%	+13.33%	+42.13%	-	12.97B
Average	+2.85%	+3.60%	+41.53%	+121.46%	23.59B
Weighted average by Cap.	+2.99%	+6.60%	+58.32%	+136.93%

	2024	2025
Net sales	500K 439K 404K 377K 710K 47.54M 725K 4.86M 1.88M 23.33M 1.88M 1.84M 81.21M	-
Net income	-9.7M -8.52M -7.84M -7.31M -13.78M -922M -14.06M -94.3M -36.53M -453M -36.42M -35.64M -1.58B	-4.95M -4.34M -4M -3.72M -7.02M -470M -7.17M -48.08M -18.63M -231M -18.57M -18.17M -803M
Net Debt	-6.46M -5.68M -5.22M -4.87M -9.18M -615M -9.37M -62.83M -24.34M -302M -24.27M -23.75M -1.05B	-3.57M -3.13M -2.89M -2.69M -5.07M -339M -5.17M -34.7M -13.44M -167M -13.4M -13.11M -580M